ATE391122T1 - 4 ((2,4-dichloro-5-methoxyphenyl)amino)-6-alkoxy- 7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie - Google Patents

4 ((2,4-dichloro-5-methoxyphenyl)amino)-6-alkoxy- 7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie

Info

Publication number
ATE391122T1
ATE391122T1 AT05820982T AT05820982T ATE391122T1 AT E391122 T1 ATE391122 T1 AT E391122T1 AT 05820982 T AT05820982 T AT 05820982T AT 05820982 T AT05820982 T AT 05820982T AT E391122 T1 ATE391122 T1 AT E391122T1
Authority
AT
Austria
Prior art keywords
quinolinecarbonitriles
ethynyl
ischemia
methoxyphenyl
dichloro
Prior art date
Application number
AT05820982T
Other languages
English (en)
Inventor
Diane Boschelli
Margaret Zaleska
Ana Carolina Barrios-Sosa
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE391122T1 publication Critical patent/ATE391122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05820982T 2004-10-22 2005-10-21 4 ((2,4-dichloro-5-methoxyphenyl)amino)-6-alkoxy- 7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie ATE391122T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62128004P 2004-10-22 2004-10-22

Publications (1)

Publication Number Publication Date
ATE391122T1 true ATE391122T1 (de) 2008-04-15

Family

ID=35784691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05820982T ATE391122T1 (de) 2004-10-22 2005-10-21 4 ((2,4-dichloro-5-methoxyphenyl)amino)-6-alkoxy- 7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie

Country Status (23)

Country Link
US (1) US20060116375A1 (de)
EP (1) EP1802581B1 (de)
JP (1) JP2008517924A (de)
KR (1) KR20070085413A (de)
CN (1) CN101044117A (de)
AT (1) ATE391122T1 (de)
AU (1) AU2005299822A1 (de)
BR (1) BRPI0516995A (de)
CA (1) CA2581807A1 (de)
CR (1) CR9072A (de)
DE (1) DE602005005843T2 (de)
DK (1) DK1802581T3 (de)
EC (1) ECSP077385A (de)
ES (1) ES2303287T3 (de)
IL (1) IL182547A0 (de)
MX (1) MX2007004833A (de)
NO (1) NO20071708L (de)
PL (1) PL1802581T3 (de)
PT (1) PT1802581E (de)
RU (1) RU2007111704A (de)
SI (1) SI1802581T1 (de)
WO (1) WO2006047262A1 (de)
ZA (1) ZA200703275B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
WO2014086284A1 (zh) * 2012-12-04 2014-06-12 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN114436851B (zh) * 2022-01-17 2023-08-22 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Also Published As

Publication number Publication date
KR20070085413A (ko) 2007-08-27
AU2005299822A1 (en) 2006-05-04
CR9072A (es) 2007-09-07
MX2007004833A (es) 2007-05-16
PT1802581E (pt) 2008-06-03
EP1802581B1 (de) 2008-04-02
WO2006047262A1 (en) 2006-05-04
NO20071708L (no) 2007-07-13
DE602005005843T2 (de) 2009-05-14
CN101044117A (zh) 2007-09-26
CA2581807A1 (en) 2006-05-04
EP1802581A1 (de) 2007-07-04
DE602005005843D1 (de) 2008-05-15
ECSP077385A (es) 2007-05-30
PL1802581T3 (pl) 2008-09-30
ES2303287T3 (es) 2008-08-01
JP2008517924A (ja) 2008-05-29
US20060116375A1 (en) 2006-06-01
IL182547A0 (en) 2007-09-20
SI1802581T1 (sl) 2008-08-31
HK1104555A1 (en) 2008-01-18
DK1802581T3 (da) 2008-06-30
BRPI0516995A (pt) 2008-09-30
RU2007111704A (ru) 2008-11-27
ZA200703275B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
JO2282B1 (en) Oxazole derivatives
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
EA200600190A1 (ru) Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона
ECSP066760A (es) Derivado de 4-oxopirimidina de anillos condensados
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
EA200700099A1 (ru) Производные пиридина
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
EA200700756A1 (ru) Пиримидоны
EA201270266A1 (ru) Гетероциклические соединения
RU2011112684A (ru) АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
TW200727893A (en) Methods for treating sexual dysfunction
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
TW200626158A (en) Naphthaline derivatives
TW200716547A (en) Piperidin-4-yl-amide derivatives
EA200701780A1 (ru) Противоопухолевое средство

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1802581

Country of ref document: EP

REN Ceased due to non-payment of the annual fee